The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
Diffuse Large B-Cell Lymphoma | NEJM
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
Ibrutinib improves diffuse large B-cell lymphoma survival - NCI
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology
Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma | Acta Pharmacologica Sinica
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Frontiers | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas
JPM | Free Full-Text | Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma: Trends in Cancer
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma | Annals of Hematology
Cancers | Free Full-Text | Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes | MedPage Today
Trial results show that younger lymphoma patients respond well to ibrutinib | Center for Cancer Research
Overall survival following Richter transformation on ibrutinib by line... | Download Scientific Diagram
News on Diffuse Large B-Cell Lymphoma » Coping with Cancer
